The History of Axomera®

From foundational research into transepithelial potentials to a CE-certified Class IIa medical device — the development history of Axomera®.

Scientific origins

The foundations of Axomera® therapy lie in bioelectric basic research. Transdermal direct-current fields were identified as physiologically relevant for tissue regeneration and inflammation modulation as early as the 1980s. Prof. Dr. Albrecht Molsberger built on this research base and developed the clinical application over three decades.

Founding and development

• 2008 — Founding of Columbus Health Products GmbH by Prof. Dr. Molsberger and Dr. Schröder in Düsseldorf.
• 2012 — First clinical use of Axomera® in pilot centres. Start of systematic observational study.
• 2017 — CE marking under MDR (EU) 2017/745, Class IIa. Axomera® receives CE mark CE 0123.
• 2019 — Build-up of the German-speaking physician network. Axomera® introduced to additional practices.
• 2022 — Launch of systematic digital case documentation. Over 333 cases are recorded and analysed.
• 2024 — Over 250 active practices in DE, AT and CH. More than 20,000 treatments annually.

Today

Axomera® is today deployed in over 250 certified physician practices in Germany, Austria and Switzerland. The ecosystem encompasses the CE medical device, a clinical iOS app, cloud documentation and the Axomera® Campus for training and continuing education.